Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-positive/HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05038735
What this trial is testing

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 210
Testing effectiveness (Phase 2)Looking for participantsNCT05872347
What this trial is testing

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Who this might be right for
Breast Cancer Brain Metastases
Shanghai Pharmaceuticals Holding Co., Ltd 52
Large-scale testing (Phase 3)Active Not RecruitingNCT04639986
What this trial is testing

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 331
Large-scale testing (Phase 3)Temporarily pausedNCT05503108
What this trial is testing

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Who this might be right for
Fasting Mimicking DietHER2-negative Breast CancerHormone Receptor-positive Breast Cancer+3 more
Leiden University Medical Center 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07782840
What this trial is testing

QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Testing effectiveness (Phase 2)Active Not RecruitingNCT06957379
What this trial is testing

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Who this might be right for
HR+/HER2- Advanced/Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 78
Not applicableUnknownNCT06344780
What this trial is testing

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 200
Not applicableStudy completedNCT04736576
What this trial is testing

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy

Who this might be right for
Breast Cancer
Pfizer 99
Testing effectiveness (Phase 2)Study completedNCT03671330
What this trial is testing

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 327
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Large-scale testing (Phase 3)Not Yet RecruitingNCT07393321
What this trial is testing

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical 210
Testing effectiveness (Phase 2)Study completedNCT02404844
What this trial is testing

Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer

Who this might be right for
Breast Cancer
University Hospital, Essen 48
Not applicableLooking for participantsNCT07743944
What this trial is testing

A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
AstraZeneca 2,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07619066
What this trial is testing

A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

Who this might be right for
Advanced Breast CancerHormone Receptor Positive / HER2-negative Breast CancerHER2 Mutation
MedSIR 25
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Not applicableStudy completedNCT05912933
What this trial is testing

Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

Who this might be right for
Breast Cancer
Pfizer 1,342
Large-scale testing (Phase 3)Ended earlyNCT03050398
What this trial is testing

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 8
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233
Next Page